---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-26-000103"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2026-08-06T20:08:16+00:00"
generated_at: "2026-08-06T20:09:18.097794+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Halozyme reports record Q2 2026: revenue $481M (+48% YoY), raises full-year guidance

## Summary
- Q2 total revenue $481M (+48% YoY); royalty revenue $308M (+50% YoY); GAAP diluted EPS $1.90, non-GAAP $2.28.
- Adjusted EBITDA $329M (+46% YoY); operating income $288M.
- Raised FY2026 guidance: total revenue $1.835-1.910B, royalty $1.220-1.245B, non-GAAP EPS $8.65-9.00.
- Signed five new ENHANZE/Hypercon collaborations YTD (Vertex, Oruka, GSK, Incyte, undisclosed), exceeding full-year goal of three.
- Repurchased $333M of shares in Q2 at avg $69.30; new $1B buyback program announced.

## SEC filing metadata
- accession: 0001159036-26-000103
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2026-08-06T20:08:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000103/0001159036-26-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000103/halo-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-26-000103
- JSON: https://secwatch.observer/filing/0001159036-26-000103.json
- Plain text: https://secwatch.observer/filing/0001159036-26-000103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.